Figure 4.
(A) Predicted secondary structure of the human vesicular monoamine transporter 2 (VMAT2) and (B) two classical and now commonly used VMAT inhibitors: tetrabenazine and reserpine (Wimalasena, 2010). (C) Three dimensional homology model of the vesicular acetylcholine transporter (VAChT) (Khare et al., 2010) and (D) its most studied inhibitor: vesamicol (Kozaka et al., 2012).